Bluebird bio, which has a significant presence in Durham, has raised $75 million in a stock offering and plans to use the funds to help with the costs of spinning off 2seventy as a separate company.
Read More
Bluebird bio, a gene therapy company with manufacturing facilities in Durham, is resuming clinical trials of potential therapies for two inherited blood disorders after clearance from the U.S. Food and Drug Administration.
Read More
bluebird bio has hit a major milestone, garnering U.S. Food and Drug Administration approval to market its first product in the U.S., which is also its first cell therapy designed to treat cancer.
Read More
bluebird bio, a global gene therapy company with a new manufacturing facility in Durham, has unveiled positive results in clinical trials of its treatment for boys with a rare and deadly neurological disorder.
Read More
LentiGlobin, marketed as ZYNTEGLO, is a one-time gene therapy that addresses the underlying genetic cause of transfusion-dependent β-thalassemia (TDT), an inherited blood disorder caused by a mutation in the β-globin gene. It interferes with red blood cell production, leading to severe anemia.
Read More
Two life science firms with a big presence in the Triangle are teaming up for a joint research project targeting gene editing treatments.
Read More
Headlines from tech and life science companies in the Triangle and NC includes new funding for Novan, credit line update for Aerie, a new Piedmont Natural Gas plant, and more.
Read More
Here’s a roundup of news from Triangle-area tech and life science firms, from funding to financials to mobile health: Novan Secures Up to $35 Million in Non-Dilutive Funding Validic and Welldoc Partner to Enhance Engagement for Individuals Living with Chronic Conditions Precision BioSciences Reports First Quarter 2019 Financial Results...
Read More
bluebird bio, a Massachusetts-based gene and cell therapy company, has opened its first wholly owned manufacturing facility in Durham amid cheers from state leaders.
Read More
